Cervical Intraepithelial Neoplasia (CIN) Explained

What is Cervical Intraepithelial Neoplasia?

Cervical intraepithelial neoplasia (CIN) refers to abnormal cell changes found on the surface of the cervix (the lower part of the uterus). These changes are considered precancerous lesions, meaning they have the potential to develop into cervical cancer if left untreated. However, CIN is not cancer itself -- the abnormal cells are confined to the surface layer (epithelium) of the cervix and have not invaded deeper tissues.

CIN is classified into three grades based on the extent of abnormal cell involvement within the epithelial layers:

• CIN 1 (mild dysplasia): Abnormal cells affect only the lower third of the epithelium. This grade often resolves on its own without treatment.
• CIN 2 (moderate dysplasia): Abnormal cells involve approximately two-thirds of the epithelium. Close monitoring or treatment is usually recommended.
• CIN 3 (severe dysplasia / carcinoma in situ): The full thickness of the epithelium is affected. Treatment is strongly recommended, as the risk of progression to invasive cancer is significant.

Causes

The primary cause of CIN is a persistent infection with high-risk strains of the Human Papillomavirus (HPV). HPV is a very common sexually transmitted virus. While most HPV infections clear up on their own, certain high-risk types -- particularly HPV 16 and HPV 18 -- can cause chronic cellular changes that may progress to CIN and eventually to cervical cancer.

Additional risk factors that may contribute to the development of CIN include:

• Early onset of sexual activity
• Multiple sexual partners
• Smoking (which weakens local immune defenses in the cervix)
• Long-term use of hormonal contraceptives
• Weakened immune system (e.g., due to HIV infection or immunosuppressive therapy)
• Previous sexually transmitted infections

Symptoms

CIN typically causes no noticeable symptoms. Most women are unaware of the condition, which is why regular cervical screening is essential for early detection.

In rare cases, some non-specific symptoms may occur, such as:

• Light bleeding after sexual intercourse (post-coital bleeding)
• Unusual vaginal discharge

These symptoms are not specific to CIN and may have many other causes. Any unusual symptoms should be evaluated by a healthcare professional.

Diagnosis

CIN is typically detected during routine gynecological screening. The key diagnostic tools include:

• Pap smear (cervical cytology): A sample of cells is collected from the cervix and examined under a microscope for abnormalities. Results are classified using systems such as the Bethesda System (e.g., LSIL, HSIL).
• HPV test: This test detects the presence of high-risk HPV types. It is often performed alongside the Pap smear as a co-test.
• Colposcopy: If screening results are abnormal, a colposcopy is performed. The doctor uses a magnifying device (colposcope) to closely examine the cervix. Solutions such as acetic acid or iodine may be applied to highlight abnormal areas.
• Biopsy: Small tissue samples are taken from suspicious areas for histological (microscopic tissue) analysis to confirm the diagnosis and determine the grade of CIN.

Treatment

Treatment decisions depend on the grade of CIN, the patient's age, and individual circumstances including future pregnancy plans.

CIN 1

For mild dysplasia, a watch-and-wait approach is often recommended, as CIN 1 frequently regresses spontaneously. Regular follow-up examinations (every 6 to 12 months) are necessary to monitor the condition.

CIN 2

For moderate dysplasia, the approach may vary. In younger women who wish to preserve fertility, careful monitoring may be appropriate. In other cases, active treatment is initiated.

CIN 3

High-grade dysplasia requires prompt treatment. The most common treatment options include:

• Cone biopsy (conization): A cone-shaped piece of tissue is surgically removed from the cervix. This is the standard treatment and allows simultaneous histological examination of the removed tissue.
• LLETZ / LEEP (Large Loop Excision of the Transformation Zone): Abnormal tissue is removed using a thin wire loop with an electrical current.
• Laser conization: Abnormal tissue is removed using a laser beam.
• Cryotherapy: The abnormal tissue is frozen and destroyed (less commonly used today).

Prevention

The most effective preventive measure against CIN is the HPV vaccine, which protects against the most common cancer-causing HPV types. The World Health Organization (WHO) recommends HPV vaccination for girls aged 9 to 14 as the primary target group, before they become sexually active. In many countries, boys are also vaccinated. Regular cervical cancer screening remains essential even for vaccinated individuals, as the vaccine does not protect against all HPV types.

References

1. World Health Organization (WHO): Human papillomavirus (HPV) and cervical cancer. Fact Sheet, 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
2. Moscicki A.B. et al.: Updating the Natural History of Human Papillomavirus and Anogenital Cancers. Vaccine, 2012; 30(Suppl 5): F24-F33.
3. Luesley D., Leeson S. (Eds.): Colposcopy and Programme Management -- Guidelines for the NHS Cervical Screening Programme. NHSCSP Publication No. 20, 2nd Edition, 2010.